Business
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nRevenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data\n\nRaises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20%\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025.\n\nFirst Quarter 2025 Financial Highlights\n\nFor the three-month period ended March 31, 2025, as compared to the same period of 2024:\n\n\nReported total revenue of $203.5 million, an increase of 21%, driven by:\n\n\nOncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25%\n\n\nScreening revenue of $5.7 million, and approximately 9,000 Shield screening tests\n\n\nBiopharma & Data revenue of $45.4 million, an increase of 21%\n\n\n\n\nIncreased Guardant360 ASP to a new range of $3,000 to $3,100 per test\n\n\nAchieved positive gross margins for both Guardant Reveal and Shield\n\n\nRecent Operating Highlights\n\n\nReceived ADLT status from CMS for Shield, increasing the Medicare pricing to $1,495\n\n\nReceived first Shield payor coverage for average-risk individuals age 45 and older from the VA Community Care Network, representing over 9 million beneficiaries\n\n\nPresented Shield multi-cancer data across ten cancer types at AACR 2025, demonstrating 60% overall sensitivity, 98.5% specificity, and 89% accuracy for cancer site of origin prediction\n\n\nLaunched upgraded Guardant360 Tissue, representing the first broad multiomic tissue CGP test to incorporate DNA, RNA, AI-powered PD-L1, and genome-wide methylation\n\n\nAnnounced a multi-year global collaboration with Pfizer to support development and commercialization of new cancer therapies utilizing the Infinity smart liquid biopsy platform\n\n\nAnnounced first publication of Reveal breast cancer data in Clinical Cancer Research demonstrating 83% sensitivity and 99.5% specificity for triple-negative breast cancer patients\n\n\n“We started the year with very strong momentum across our portfolio, fueled by ground-breaking product upgrades and new tests introduced in 2024 which leverage our smart liquid biopsy platform,” said Helmy Eltoukhy, co-founder and co-CEO. “Earlier this week, we were excited to launch our upgraded Guardant360 Tissue, a fir...